Voyager Therapeutics (VYGR) Total Liabilities (2014 - 2026)

Voyager Therapeutics has disclosed Total Liabilities across 13 years of filings, most recently posting $45.7 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $45.7 million, down 43.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.7 million (down 43.31% YoY), and the FY2025 annual result was $56.2 million, down 39.76% from the prior year.
• Total Liabilities came in at $45.7 million for Q1 2026 at Voyager Therapeutics, down from $56.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $148.3 million in Q1 2022 to a low of $45.7 million in Q1 2026.
• The 5-year median for Total Liabilities is $100.8 million (2024), against an average of $99.8 million.
• Across the five-year window, Total Liabilities jumped 46.05% in 2022 and slumped 43.31% in 2026, its largest moves.
• Voyager Therapeutics' Total Liabilities stood at $100.3 million in 2022, then climbed by 14.58% to $115.0 million in 2023, then fell by 18.85% to $93.3 million in 2024, then slumped by 39.76% to $56.2 million in 2025, then dropped by 18.76% to $45.7 million in 2026.
• The last three Total Liabilities figures came in at $45.7 million (Q1 2026), $56.2 million (Q4 2025), and $68.5 million (Q3 2025), per Business Quant data.